Products
Platform
Research
Market
Learn
Compare DSP Healthcare Fund vs Tata India Pharma & Healthcare Fund
Fund Comparison
Detailed comparison on parameters like NAV | Returns | Risk | Rating | Analysis
Fund Details
Risk | Very High | Very High |
Rating | 4.0 | 3.0 |
Min SIP Amount | ₹100 | ₹100 |
Expense Ratio | 1.91 | 2.1 |
NAV | ₹40.32 | ₹31.22 |
Fund Started | 12 Nov 2018 | 04 Dec 2015 |
Fund Size | ₹3056.90 Cr | ₹1281.99 Cr |
Exit Load | Exit load of 0.50% if redeemed within 1 month. | Exit load of 0.25% if redeemed within 30 days. |
Risk
Very High
Very High
Rating
4.0
3.0
Min SIP Amount
₹100
₹100
Expense Ratio
1.91
2.1
NAV
₹40.32
₹31.22
Fund Started
12 Nov 2018
04 Dec 2015
Fund Size
₹3056.90 Cr
₹1281.99 Cr
Exit Load
Exit load of 0.50% if redeemed within 1 month.
Exit load of 0.25% if redeemed within 30 days.
Returns
1 Year | 7.88% | 7.99% |
3 Year | 24.97% | 24.06% |
5 Year | 21.24% | 20.16% |
1 Year
7.88%
7.99%
3 Year
24.97%
24.06%
5 Year
21.24%
20.16%
Holding Analysis
Equity | 98.31% | 92.31% |
Cash | 1.69% | 7.69% |
Equity
98.31%
92.31%
Cash
1.69%
7.69%
Top Holdings
Top 10 Holdings |
|
|
Top 10 Holdings
Name | Assets |
|---|---|
Cipla Ltd. | 8.82% |
Sun Pharmaceutical Industries Ltd. | 8.42% |
Cohance Lifesciences Ltd. | 7.88% |
Ipca Laboratories Ltd. | 7.71% |
Gland Pharma Ltd. | 5.52% |
Laurus Labs Ltd. | 5.26% |
Alembic Pharmaceuticals Ltd. | 4.85% |
Apollo Hospitals Enterprise Ltd. | 4.61% |
Globus Medical Inc | 4.44% |
Sai Life Sciences Ltd. | 4.31% |
Name | Assets |
|---|---|
Sun Pharmaceutical Industries Ltd. | 11.17% |
Apollo Hospitals Enterprise Ltd. | 7.19% |
Cipla Ltd. | 5.76% |
Divi's Laboratories Ltd. | 5.58% |
Aurobindo Pharma Ltd. | 5.44% |
Fortis Healthcare Ltd. | 5.30% |
Lupin Ltd. | 4.58% |
Aster DM Healthcare Ltd. | 4.45% |
Wockhardt Ltd. | 3.67% |
Alkem Laboratories Ltd. | 2.90% |
Fund Manager
Name | Jay Kothari | Meeta Shetty |
Start Date | 16 Mar 2018 | 09 Nov 2018 |
Name
Jay Kothari
Meeta Shetty
Start Date
16 Mar 2018
09 Nov 2018
About Fund
Description | The scheme seeks to generate consistent returns by predominantly investing in equity and equity related securities of pharmaceutical and healthcare companies. | The scheme seeks long term capital appreciation by investing atleast 80% of it's net assets in equity/equity related instruments of the companies in the pharma & healthcare sectors in India. |
Launch Date | 12 Nov 2018 | 04 Dec 2015 |
Description
The scheme seeks to generate consistent returns by predominantly investing in equity and equity related securities of pharmaceutical and healthcare companies.
The scheme seeks long term capital appreciation by investing atleast 80% of it's net assets in equity/equity related instruments of the companies in the pharma & healthcare sectors in India.
Launch Date
12 Nov 2018
04 Dec 2015
